Scholarlink

<p>Rheumatoid arthritis (RA) is a prevalent and debilitating inflammatory disease that significantly impairs functional capacity and quality of life. RA accelerates musculoskeletal aging, leading to complications such as muscle degeneration and <i>sarcopenia</i>. Recent research has identified <i>myopenia</i> as a condition of significant muscle loss associated with illness, distinct from the muscle wasting seen in other chronic diseases like cancer cachexia or heart failure. In RA, <i>myopenia</i> is characterized by muscle depletion without concurrent significant fat loss, and it can affect individuals of all ages. While inflammation plays a central role, it is not the sole factor contributing to the high incidence of muscle wasting in RA. In subsequent discussions, <i>secondary sarcopenia</i> will be considered alongside <i>myopenia</i>, as both involve muscle wasting decline primarily due to disease. This review summarizes recent findings on the impact of RA-related <i>myopenia</i> and <i>secondary sarcopenia</i> on functional capacity, explores its underlying mechanisms, and discusses contemporary strategies to mitigate the process of musculoskeletal aging in RA patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pathophysiology of Myopenia in rheumatoid arthritis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月16日

查看全文
  • Haiming Jin,
  • Gang Wang,
  • Qichen Lu,
  • Jessica Rawlins,
  • Junchun Chen,
  • Saanya Kashyap,
  • Oscar Charlesworth,
  • Dan Xu,
  • Lie Dai,
  • Sipin Zhu,
  • Jiake Xu

摘要

Rheumatoid arthritis (RA) is a prevalent and debilitating inflammatory disease that significantly impairs functional capacity and quality of life. RA accelerates musculoskeletal aging, leading to complications such as muscle degeneration and sarcopenia. Recent research has identified myopenia as a condition of significant muscle loss associated with illness, distinct from the muscle wasting seen in other chronic diseases like cancer cachexia or heart failure. In RA, myopenia is characterized by muscle depletion without concurrent significant fat loss, and it can affect individuals of all ages. While inflammation plays a central role, it is not the sole factor contributing to the high incidence of muscle wasting in RA. In subsequent discussions, secondary sarcopenia will be considered alongside myopenia, as both involve muscle wasting decline primarily due to disease. This review summarizes recent findings on the impact of RA-related myopenia and secondary sarcopenia on functional capacity, explores its underlying mechanisms, and discusses contemporary strategies to mitigate the process of musculoskeletal aging in RA patients.